Researchers have discovered discrepancies in the efficacy of alprazolam (Xanax XR), a widely prescribed benzodiazepine sedative, when analyzing both published and unpublished clinical trial data. The study found that only one of the five FDA-reviewed trials showed a clearly positive outcome.from Neuroscience News https://ift.tt/I6EgdaU
Comments
Post a Comment